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Abstract: Phagotherapy, the use of bacteriophages to fight bacterial infections as an alternative to 
antibiotic treatments, has become of increasing interest in the last years. This is mainly due to the 
diffusion of multi-drug resistant (MDR) bacterial infections that constitute a serious issue for public 
health. Phage therapy is gaining favor due to its success in agriculture and veterinary treatments 
and its extensive utilization for human therapeutic protocols in the Eastern world. In the last 
decades, some clinical trials and compassionate treatments have also been performed in the Western 
world, indicating that phage therapy is getting closer to its introduction in standard therapy 
protocols. However, several questions concerning the use of phages in human therapeutic 
treatments are still present and need to be addressed. In this review, we illustrate the state of art of 
phage therapy and examine the role of animal models to translate these treatments to humans. 
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1. Phages for Therapy: Positive and Negative Outcomes 
Bacteriophages (phages) are viruses that specifically infect and multiply within the bacteria [1]. 
The use of phages to counteract bacterial infection dates to almost one century ago, and their use has 
never been abandoned completely, although it was mostly eclipsed by the advent of antibiotics. 
Nowadays, phages are regaining interest to overcome the development of antibiotic resistant bacteria 
[2]. However, phages are extremely appealing but also frightening in some aspects, particularly due 
to the incomplete knowledge of their mechanism of action. In the first part of this review, we describe 
phage characteristics, highlighting positive and negative aspects for their use in clinics (Figure 1). 
 
Figure 1. Positive and negative outcomes of phages. 
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The end point of phage infection is the death of the bacterium, usually through its lysis, and the 
release of progeny virions. Phages that have only this way of multiplication are called lytic phages 
and are suitable for phage therapy. Other phages, called lysogenic, may parasitize the host, leaving 
their genome inside the infected bacterium for generations [3]. In the lysogenic condition, the 
bacterium acquires immunity to superinfection of phages of the same type, a bad outcome for the 
purpose of phage therapy. Therefore, lysogenic phages are not used for therapy [4]. 
Another negative feature of several phages is their ability to transduce parts of the bacterial 
genome following the infection. This could cause the transmission of noxious or virulence genes in 
the bacterial population [5]. The possibility of the transducing ability of the phage used for therapy 
has to be checked. Moreover, some phages contain potentially harmful genes in their genomes. It is 
good practice to analyze the whole genome of the phage used for phage therapy to exclude it. Phage 
genome analyses could be a time-consuming technique incompatible with the need for urgent 
infection treatments in which phages are able to infect the bacteria of the patients and should be 
quickly identified and administered. 
In phage therapy, it is appropriate to decide whether to use a single phage or a mix (cocktail) of 
phages with different characteristics. Given the high specificity of phage infection for a certain 
bacterial strain, the use of multiple phages is often better at containing an infection [6]. In particular, 
if the bacterial strain undergoes a mutation to resistance (e.g., mutation of the bacterial gene encoding 
the specific receptor necessary for phage adsorption or mutation in a bacterial function essential for 
phage reproduction), the presence of phages using different receptors or alternative functions will 
overcome the defeat of a single phage by the success of another. In addition, the use of phage cocktails 
that infect different bacterial species is often used in cases of skin infections in which different 
bacterial species are normally present [7]. 
Custom-designed phage cocktails are currently used for therapeutic treatments in countries of 
Eastern Europe, especially Georgia, where bacteriophages preparations are considered as 
pharmaceutics and prepared in authorized pharmacies. In Western countries, the situation is more 
complicated, mainly because no current rules for the use of phages as drugs have been developed 
until now. Indeed, as one of the main goals of phage therapy is the tailored treatment of an acute 
infection of an individual patient, it is difficult to apply the standard methods used for medical 
products (i.e., random and double-blinded clinical trials) for their commercialization. Moreover, non-
engineered phages are natural compounds that cannot be patented, thus making their production of 
poor economic interest [8]. Recently, a few clinical trials have also been conducted in Western 
countries [9], and patient-tailored-phage therapy has been used for compassionate studies, such as to 
counteract Acinetobacter baumanii, Pseudomonas aeruginosa, and Mycobacterium abscessus infections [10–
12]. Phage cocktails were prepared by combining the efforts of different laboratories and then 
intravenously injected in the patients and used in combination with antibiotics. All the published 
phage therapies were effective against the life-threatening disseminated infections of the patients. 
Considering the time required for isolating phages from the environment, it would be of great 
interest to generate a phage bank containing libraries of characterized phages and a phage 
preparation storage at higher phage titer for rapid delivery, as is done in the Eastern countries [13]. 
One intriguing scenario could be the generation of a bank containing phages targeting all the multi-
drug resistant (MDR) bacteria isolated from patients in each sanitary structure. 
Phage preparation for human medical uses requires strict purification protocols to prevent 
endotoxin contamination. For studies in animal models, a sufficient degree of purification is achieved 
by CsCl gradient ultra-centrifugation [14] with subsequent endotoxin removal. Chromatographic 
methods can be also used for phage purification as well [15]. In chromatography-purified phages, 
endotoxin levels are decreased 10- to 30-fold with respect to the traditional method, but often the 
final phage titer is lower. 
For human administration, the upper endotoxin (EU) threshold was defined at 5 EU/kg per h 
according to European Pharmacopeia regulations (FDA guideline, QAS11-452_FINAL_July12). 
Specialized institutes such as the Center for Phage Technology (CPT) or the Eliava Institute of Tblisi 
(Georgia) produce and provide large-scale, highly purified phages for clinical or research purposes 
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[10,16–20]. Stability of phage preparations is essential to achieve efficient phage administration over 
time. 
However, since each specific phage is different from another in its sensitivity to chemical and 
environmental factors, a universal strategy for their preparation is not possible yet. Usually, phages 
are resuspended in simple aqueous solutions. However, a gradual loss of phage activity can be 
observed during long-term storage of phage solutions, and, therefore, stabilizers must be added. 
Given the proteinaceous nature of phage capsids, protein stabilizers are usually added to phage 
preparations, including sugars (e.g., sucrose) and polymers (e.g., polyethylene glycol) [15]. 
Alternatively, phage solutions can be lyophilized and converted into powder with a high grade of 
stability [21]. 
2. Animal Models for Testing Phage Therapy 
In the last years, several animal models of the most common and relevant human bacterial 
infections have been created and used to test newly isolated phages and their efficacy in fighting 
these pathogens in vivo [22]. Animal models of bacterial infection are necessary tools to (i) verify the 
efficacy of phage therapy in vivo, (ii) search for possible adverse effects, (iii) unravel interactions with 
the host (e.g., immune system activation). In the second part of this review, we describe how the 
generation of animal models of bacterial infections might help in the translation of phage therapy to 
human clinics. 
2.1. Phage Therapy and Antimicrobial Action Using Invertebrate and Vertebrate Animal Models 
Among the main used invertebrate or lower vertebrate models for phagotherapy, there are 
nematode (Caenorhabditis elegans), common fruit fly (Drosophila melanogaster), wax moth (Galleria 
mellonella), and zebrafish (Danio rerio), while for higher vertebrate, there are chicken (Gallus gallus), 
rabbit (Oryctolagus cuniculus), hamster (Mesocricetus auratus), and mouse (Mus musculus) models 
(Figure 2). 
 
Figure 2. Animal models used for bacterial infection and phage therapy application. 
C. elegans is a small-size nematode (1 mm in length) that can be easily infected by bacteria, fungi, 
and virions inducing lethality of non-lethal infections [23,24]. The long list of pathogens infecting C. 
elegans also includes common human bacteria such as P. aeruginosa. Moreover, bacterial virulence 
factors that induce lethality in nematode are conserved in mammals, opening new opportunities in 
the use of C. elegans for large screening studies. While avoiding professional immune cells, in C. 
elegans, the defense to pathogens is mediated by epithelial cells that activate autophagy and the 
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immune system though the production of antimicrobial proteins, peptides (AMPs), and p38 pathway 
activation [25]. The infection in nematodes can be easily achieved, as their nutritional source is the 
bacteria, thus pathogens primarily colonize the intestine, and phages can be delivered via the same 
route of administration. Augustine et al. (2014) and Glowacka-Rutkowska et al. (2019) [26,27] 
established C. elegans models for Salmonella enteritidis and Staphylococcus aureus infections and phage 
therapy application. In both cases, the bacteriophage administration resulted in a considerable 
increase in the survival of infected larvae. Remarkably, the healthy state of the recovered nematodes 
was confirmed by the fact that they produced healthy progeny after 100 h after phage treatment. 
Although these two studies take into account the mortality as a unique parameter for testing a 
phage’s efficacy and effects, the results indicated that C. elegans can be a useful animal model for these 
studies. 
Among non-vertebrate infection models, insects have a strong potential due to their complex 
innate immune system, which shows high similarity to those of mammals [28,29]. Moreover, they are 
considered suitable alternative models to larger mammals for bacterial colonization studies and 
excellent tools for pharmacokinetic studies of antimicrobials [28,30,31]. In two different studies, D. 
melanogaster was used to evaluate the therapeutic effect of phages against P. aeruginosa infections. In 
the first study done by Lindberg et al. (2014) [32], the authors investigated the pharmacokinetics and 
the possible toxicity of phages by themselves. Phage solutions were mixed to corn meal-dextrose 
medium and administered to healthy flies. The presence of live bacteriophages in the flys’ lysates at 
different time points after treatment demonstrated that phages survived and were not degraded in 
the gastrointestinal system. This suggests that oral administration can be successfully studied in 
animal models, highlighting the interesting possibility of using D. melanogaster to test oral 
administration of phages. Moreover, the absence of lethality after phage administration indicates that 
phage treatments are safe and free of toxicity. In the second work done by Heo et al. (2009) [33], the 
authors compared the effects of P. aeruginosa infection and phage administration in mice and D. 
melanogaster. The use of two infection models is important to confirm the antibacterial activity of 
phages against P. aeruginosa that activates different virulence factors depending on the host. Given 
the promising potential of D. melanogaster as a simple, rapid and cheap animal model to conduct 
studies on bacterial infection and phage therapy, a guided protocol has recently been set up to 
evaluate the antibacterial efficacy of new bacteriophages against P. aeruginosa infection in this model 
[34]. 
Another invertebrate used for microbial infection and phage therapy is G. mellonella. In a study 
done by Seed et al. (2009) [35], different bacteriophages were efficiently administrated in G. mellonella 
larvae to treat Burkholderia cepacia infection. The authors also addressed if the protective effect 
observed in the treated larvae was due to bacteriophages’ action rather than to the reaction of the 
immune system of the host triggered by the phage injection. They found that heat-inactivated phages 
activated the immune system but did not improve larvae survival, indicating that the antibacterial 
action depended on active phage multiplication. Interestingly, two different studies in wax moth 
larvae also reported a prophylactic efficacy when phage cocktail was injected or orally administrated. 
In the first study done by Nale et al. (2016) [36], a four-phage cocktail able to disrupt C. difficile biofilm 
was effective in increasing survival when added to the larvae food, preventing bacterial colonization. 
In a second study done by Forti et al. (2018) [37], the six-phage cocktail initially used to prevent P. 
aeruginosa infections in G. mellonella efficiently counteracted lung infections in the mouse. This result 
showed that the same bacteriophages can function in different species, both invertebrates and 
vertebrates. 
Zebrafish is gaining favor as a model for the study of host-bacterial interactions, especially in its 
embryonic stage [38–40]. The presence of a developed innate immune system, genetic tractability, 
and optical transparency of the embryos make it useful for studying aspects of infectious diseases not 
accessible in traditional animal models. Recently, some zebrafish models were set up to study 
bacterial infections such as Enterococcus faecalis and P. aeruginosa for phage therapy application [41,42]. 
Systemic infection in zebrafish embryos is performed through the injection of bacteria in the 
circulation followed by phage administration via the same route. The success of phage therapy 
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treatment was demonstrated by an increased survival of the infected zebrafish embryos, their 
recovery from the altered morphology caused by bacterial infection, and decreased bacterial burden 
after plating homogenized embryos. This vertebrate model validates the efficiency of phage therapy 
in a quick (five days) and cheap way and demonstrates the survival and the efficacy of phages 
delivered in the blood with an aquatic model. 
The use of invertebrates and lower vertebrates such as zebrafish presents several advantages for 
the research, such as reduced cost and experimental procedure time. However, to translate phage 
therapy to humans, it is also necessary to use higher vertebrate models. For instance, in birds, oral 
phage administration was applied as prophylaxis or post-infection treatment to counteract 
salmonellosis, colibacillosis, and campylobacteriosis infections that represent a worldwide economic 
and health problem in poultry [43,44]. Some studies also investigated the use of encapsulated phages 
of part of the virion, such as the tailspike domain, to improve phage therapy in chickens [45–47]. 
Given the importance of phage therapy application using birds as animal models, a procedure to test 
phage efficacy using a chicken embryo of colibacillosis infection was recently described [48]. 
Rabbits were also used as a model of S. aureus wound infection followed by phages 
administration [49]. As with humans, but contrary to mice, rabbits naturally suffer for S. aureus 
infections, representing a suitable animal model to study the invasion of these pathogens. The 
bacterial infection was performed by subcutaneous injections that generated abscesses. Phage 
administration was performed simultaneously to bacteria or immediately after but in the same 
location. To evaluate the efficacy of phage therapy, animals were killed four or six days after infection, 
and the bacterial load in the abscesses area was evaluated. In another study presented by Kishor et 
al. (2016) [50] and commented upon by Abedon (2016) [51], phage therapy was tested in a rabbit 
model of S. aureus infection. Although authors demonstrated the feasibility of phage therapy to cure 
bacterial infection, the rabbit model was different from the patient’s situation in which bacterial 
infection was chronic, and phage therapy was applied after the failure of conventional approaches. 
A prophylactic effect of phages to prevent or reduce bacterial infection was demonstrated in new-
born mouse and rabbit models infected by Vibrio cholerae by Yen et al. (2017) [52]. 
An interesting work by Nale et al. (2016) [53] demonstrated that hamsters infected with 
Clostridium difficile and orally administered with phage cocktail showed increased survival rate. Due 
to the lack of virulent lytic phages infecting C. difficile, in this study, temperate phages were used. 
Thus, it was unsuitable for therapeutic treatment. However, the authors showed how the 
combination of multiple phage types might limit their harmful impact. 
Among mammals, murine models are the most frequently used to study phage therapy. Given 
their high similarity with humans, they have been used not only to demonstrate the efficacy of the 
classical phage therapy [37,54–57] but also to investigate the interactions between phages and the 
host immune system. This second issue is treated in detail in the following chapter. 
In Table 1, we resume the studies on animal models and antibacterial activity of phages.
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Table 1. Animal models of human phage therapy for common human pathogens. 
Animal  
Model 
Challenge 
(Pathogen) 
Condition Phage Treatment 
Route of 
Administration 
Results 
Summary 
Reference 
C. elegans 
Salmonella enterica; 
spread on agar plate 
lethal 
systemic 
infection 
mono-phage, delay (24 hpi); 5 × 109–1× 1010 pfu 
in growth 
medium 
>survival rate 
Augustine et 
al., 2014 [26] 
C. elegans 
Staphylococcus aureus; 
spread on agar plate 
lethal 
systemic 
infection 
mono-phage, delay (24 hpi); 109 pfu/ml 
in growth 
medium 
>survival rate 
Glowacka-
Rutkowska et 
al., 2019 [27] 
D. 
melanogaster 
Pseudomonas aeruginosa; 
intrathorax injection of 
103 cfu/fly 
lethal 
systemic 
infection 
mono-phage, delay (6 hpi); 104 pfu/fly 
intrathorax 
injection 
>survival rate 
Lindberg et 
al., 2014 [32] 
D. 
melanogaster 
Pseudomonas aeruginosa; 
intrathorax injection of 
50–200 cfu/fly 
lethal 
systemic 
infection 
mono-phage, co-adm; 106 pfu/fly oral (force feed) >survival rate; <BB 
Heo et al., 
2009 [33] 
G. mellonella 
Clostridium difficile; oral 
administration 105 
cfu/larva 
lethal 
systemic 
infection 
4-phage cocktail: proph (2 hbi), delay (2 hpi) or 
co-adm; 1 to 4 doses of 106 pfu/larva 
oral 
reduced mortality (100% in proph); dose-
dependence 
Nale et al., 
2016 [36] 
G. mellonella 
Burkholderia cepacia; 
injection of 2,5 × 103 
cfu/larva 
lethal 
bacteremia 
mono-phage, delay (6 or 12 hpi); 2,5 × 103 
pfu/larva 
injection >survival rate; <BB 
Seed et al., 
2009 [35] 
G. mellonella 
Pseudomonas aeruginosa 
(lab and clinical strains); 
injection of 30 cfu/larva 
lethal 
bacteremia 
6-phage cocktail: proph (1 hbi) or delay (1 hpi); 
1,5 to 4,5 × 103 pfu/larva 
injection prolonged survival time after infection 
Forti et al., 
2018 [37] 
G. mellonella 
Acinetobacter baumanii 
(XDR); injection of 5 × 
105 cfu/larva 
lethal 
bacteremia 
2-phage cocktail or mono-phage, delay (0,5 
hpi); 5 × 107 pfu/larva 
injection >survival rate (≥80%) 
Leshkasheli et 
al., 2019 [57] 
Zebrafish 
Enterococcus faecalis 
(clinical strain); injection 
in circulation of 3 × 104 
cfu/embryo 
lethal 
systemic 
infection 
mono-phage, delay (2 hpi); 6 × 105 pfu/embryo 
in 2 nL 
injection in 
circulation 
>survival rate (of 57%); >healthy state 
Al-Zubidi et 
al., 2019 [41] 
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Zebrafish 
Pseudomonas aeruginosa; 
injection in circulation of 
30 cfu/embryo 
lethal 
systemic 
infection 
4-phage cocktail, delay (0,5 or 7 hpi); 500–1000 
pfu/embryo in 2 nL 
injection in 
circulation 
>survival rate (of about 30%); <BB; reduced 
inflammatory response 
Cafora et al., 
2019 [42] 
Quail 
Salmonella enterica 
(Enteriditis); oral 
administration of 1.2 × 
108 cfu/quail 
gastrointesti
nal infection 
mono-phage, proph or delay *; 105 pfu/mL, 3 
doses daily 
oral (oral 
gavage or vent 
lip) 
<BB in cecal tonsils 
Ahmadi et al., 
2016 [43] 
Chicken 
Salmonella enterica 
(Typhimurium); oral 
administration of 107 
cfu/chicken 
gastrointesti
nal infection 
3-phage cocktail (liposome/alginate 
encapsulated), delay (24 hpi); 109/1010 
pfu/chicken, 8 doses daily 
oral <BB in cecum (of 1,5–3,9 Log10 cfu) 
Colom et al., 
2015, 2017 
[45,46] 
Rabbit 
Staphylococcus aureus; 
subcutaneous injection 
of 8 × 107 cfu/rabbit 
local 
infection 
(abscess) 
mono-phage, co-adm or delay (6, 12 or 24 hpi); 
2 × 109 pfu/rabbit 
subcutaneous 
injection 
<BB of infected area and abscesses 
prevention in co-adm (no effect in delay) 
Wills et al., 
2005 [49] 
Rabbit 
Staphylococcus aureus 
(MRSA); Intramedullary 
injection of ≤5 × 106 
cfu/rabbit (*) 
chronic 
osteomyeliti
s 
7-phage cocktail, delay (21, or 42 dpi); 5 × 1011 
pfu/rabbit, 4 doses total every 2 days 
Intralesional 
injection 
cure of infection in 21 dpf treatment 
Kishor et alet 
al., 2016 [50] 
Rabbit 
Vibrio cholerae; oral 
administration of 5 × 108 
cfu/rabbit 
gastrointesti
nal infection 
3-phage cocktail: proph (3 or 24 hbi); 4–8 × 109 
pfu/rabbit 
oral 
prevention of diarrheal symptoms; < BB in 
intestine (of 1–4 Log10 cfu) 
Yen et al., 2017 
[52] 
Hamster 
Clostridium difficile; oral 
administration of 2 × 103 
spores/hamster 
gastrointesti
nal infection 
2,3,4-phage cocktails or mono-phage, delay *;8 
× 107 pfu/mL, every 8 h × 36 hpi 
oral < BB in cecum and colon (of 2 Log10 cfu) 
Nale et al., 
2017 [53] 
Pig 
Escherichia coli (ETEC); 
oral administration of 
1010 cfu/pig 
gastrointesti
nal infection 
2,3-phage cocktail or mono-phage, proph (0,25 
hbi, 3 × 109–1010 pfu/pig) or delay (24 hpi, 6 
doses every 3 h, 108 pfu/pig) 
oral diarrhea symptoms ameliorate 
Jamalludeen et 
al., 2009 [58] 
Murine 
Pseudomonas aeruginosa, 
intranasal injection of 1 
× 107 cfu/mouse 
lethal 
respiratory 
infection 
6-phage cocktail, delay (2 hpi); 107 pfu/mouse 
intranasal 
injection 
100% reduced mortality; <BB (about 3 Log10 
times) 
Forti et al., 
2018 [37] 
Murine 
Pseudomonas aeruginosa, 
intranasal injection of 
2,5 × 107 cfu/mouse 
respiratory 
infection 
3-phage cocktail: proph (48 hbi), co-adm or 
delay (24 hpi); 1,24 ×109 pfu/mouse 
intranasal 
injection 
>survival rate; bacterial clearance in BALs 
(proph 71%, co-adm 100% and delay 86%); 
reduced inflammatory response 
Pabary et al., 
2016 [54] 
Murine 
Pseudomonas aeruginosa 
(MDR), intraperitoneal 
lethal 
bacteremia 
mono-phage, co-adm; 1 ×109 pfu/mouse 
intraperitoneal 
injection 
85% reduced mortality; bacterial clearance 
in blood; reduced inflammatory response 
Alvi et al., 
2020 [55] 
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injection of 107 
cfu/mouse 
Murine 
Pseudomonas aeruginosa 
(clinical strain), 
intranasal injection of 
107 cfu/mouse 
lethal lung 
infection 
mono-phage,  proph (24 hbi) or delay (2, 4, 6 
hpi); 108 pfu/mouse 
intranasal 
injection 
>survival rate: delay-dependent (from 100% 
in 2 hpi to 25% in 6 hpi) and 100% in proph; 
reduced inflammatory response 
Debarbieux et 
al., 2010 [56] 
Murine 
Acinetobacter baumanii 
(XDR), intraperitoneal 
injection of 6 × 107 
cfu/mouse 
lethal 
bacteremia 
2-phage cocktail or mono-phage, delay (2 hpi); 
6 × 109 pfu/mouse 
intraperitoneal 
injection 
>survival rate (≥80%) 
Leshkasheli et 
al., 2019 [57] 
Murine 
Klebsiella pneumoniae, 
topical administration 
50 ul of 108 cfu/mL 
burn wound 
infection 
5-phage cocktail or mono-phage, delay (6 hpi); 
50 uL of 108 pfu/ml 
topical 
<BB in skin tissue; faster wound healing; 
reduced inflammatory response 
Chadha et al., 
2016 [59] 
Murine 
Mycobacterium ulcerans, 
subcutaneous injection 
of 105.5 afb 
local 
infection 
(ulceration) 
mono-phage, delay (33 dpi); 108 pfu/mouse 
subcutaneous 
injection 
<BB in skin tissue; prevent ulceration 
Trigo et al., 
2013 [60] 
Murine 
Staphylococcus aureus 
(MRSA), subcutaneous 
injection of 107 
cfu/mouse 
local 
infection 
(abscess) 
mono-phage, co-adm or delay (4 dpi); 109 
pfu/mouse 
subcutaneous 
injection 
prevent/ameliorate abscess development 
Capparelli et 
al., 2007 [61] 
Murine 
Staphylococcus aureus 
(MRSA), intravenous 
injection of 108 
cfu/mouse 
systemic 
infection 
mono-phage, co-adm; 109 pfu/mouse 
intravenous 
injection 
97% reduced mortality; bacterial clearance 
in blood 
Capparelli et 
al., 2007 [61] 
Murine 
Klebsiella pneumoniae, 
intranasal instillation of 
109 cfu/mL 
Lung 
infection 
mono-phage, delay (2 hpi); 109 pfu/mouse 
intranasal 
instillation 
<BB in lung and serum; prevent severe lung 
lesions 
Anand et al., 
2019 [62] 
hbi = hours before initial infection; hpi = hours post initial infection; dpi = days post initial infection; cfu = colony-forming-units; pfu = plaque-forming-units; afb = 
acid fast bacilli; BB = bacterial burden (or bacterial load); delay = delayed treatment; co-adm = co-administration; proph = prophylactic treatment; MDR = multi drug 
resistant; XDR = extensively drug resistant; MRSA = methicillin-resistant Staphylococcus aureus; ETEC = enterotoxigenic E. coli; BAL = bronchoalveolar lavage; n° of 
doses = 1 if not differently indicated; * = not described. 
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2.2. Phages and Immune System Interactions Studies Using Animal Models 
Mouse models of bacterial infection and phage treatment have also been used to investigate 
different aspects of phage activity in vivo, such as the interaction between phages, bacteria, and the 
host immune system. For example, Abd El-Aziz and colleagues (2019) [63] used a mouse model of P. 
aeruginosa infection to investigate the synergism between phages and the innate immunity of the host 
considering the activity of phages in serum. When the serum and the phages were added to the 
bacterial culture, an increased antimicrobial activity of phages was achieved. On the contrary, when 
heat-inactivated serum was added, the phage antimicrobial activity was not increased. This might 
explain why phages are more efficient in counteracting bacterial infection when administered 
intravenously than in lungs of infected mice. 
Roach et al. (2017) [64] used immunodeficient mice Myd88−/−, Rag−/−, Il2rg−/−, and a neutrophil-
depleted line to dissect the contribution of immunity cells to phage–host synergy. Upon P. aeruginosa 
infection, only the neutrophils-depleted mice were completely unresponsive to phage treatment. 
Rag−/− and Il2rg−/− mice lacking two key genes for lymphocyte function behaved as the wild-type. 
An intermediate situation with an initial response followed by the proliferation of phage-resistant 
bacteria was achieved when Myd88, the main adaptor for Toll-like Receptor (TLR) pathway, was 
depleted. Both studies suggest an interplay between phages and innate immune response involving 
complement cascade pathway and neutrophils activity—an important aspect to consider in view of 
phage therapy application to immunodeficient patients. Another study done by Trigo et al. (2013) [60] 
investigated the immune response in a mouse footpad infected by Mycobacterium ulcerans. 
Subcutaneous phage administration reduced bacterial proliferation both in the skin and in the 
draining lymph nodes, thus preventing ulcerations. Moreover, histopathological analyses of the 
necrotic tissues of phage-treated mice showed extended macrophages and lymphocytic infiltrates, 
which colocalize with few residual bacteria, indicating a phage-mediated activation of phagocytes 
and adaptative response. 
Immune response and phage therapy were addressed also by Cafora et al. (2019) [42] in a 
zebrafish model of cystic fibrosis (CF). A P. aeruginosa systemic infection was generated in CF 
zebrafish embryos and treated effectively by phage administration. In addition, a decrease of pro-
inflammatory cytokine levels was observed in phage-treated infected embryos. Interestingly, CF 
zebrafish embryos showed a basal inflammatory status in the absence of bacterial infection similar to 
the high inflammation presented in human CF patients. Phage administration in CF embryos reduced 
the levels of pro-inflammatory cytokines, suggesting that phages might modulate the innate immune 
system and therefore opening the possibility to use bacteriophages as anti-inflammatory agents in 
conditions of constitutive inflammation. 
Another important aspect is phage immunogenicity, which is the aptitude of phages to induce 
specific immune responses with the production of specific antibodies against phage antigens. 
Opinions and data collected about phage immunogenicity in humans are few and contradictory. 
Importantly, some clinical outcomes indicate that phages widely vary in their immunogenicity 
depending on phage-type, dose, route of administration, and host immune status. In general, no strict 
dependence between phage treatment efficacy and level of antiphage-antibodies emerged [65–68]. 
Animal models contributed to shed light on this debatable question. The dynamics of phage 
immunogenicity was studied by Capparelli et al. (2007) [61] in a mouse model in which a dose of 107 
plaque forming units (pfu) of S. aureus phages were intravenously administrated at intervals of two 
weeks. Phage presence persisted in the blood circulation for approximately 21–25 days and, although 
antibodies against phages were present, they did not neutralize phage-antibacterial activity. Similar 
immunogenicity tolerance was obtained by Roach et al. (2017) [64] in a mouse model intranasally 
inoculated with a single dose of approximately 109 pfu of P. aeruginosa phages; a high degree of phage 
persistence was observed in the airways of all tested mice in the four days after the administration. 
Another study in mice was performed by Majewska et al. (2015) [69] in the absence of bacterial 
infection to analyze the immunological response of long-term exposure of T4 phage (100 days of 
continuous administration). The T4 phage was administrated in the drinkable water at a 
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concentration of 4 × 109 pfu/mL, and the evaluation of Immunoglobulin (Ig)M, IgG, and secretory IgA 
production in serum and gut was correlated to the microbiological profile of the mouse at day 240. 
IgM induction was detected only after IgG boost that started from 36 days and remained sustained 
even after phage removal from the diet. IgA secretion was detected after 79 days and gradually 
decreased after T4 removal. After 100 days, the production of IgG was dependent on the phage titer 
administration (higher dose 4 × 109 pfu/mL, lower dose 4 × 108 pfu/mL). These studies using animal 
models suggest that specific phage-humoral responses could occur, but it might be dependent on 
route, dose, and time of administration. 
An interesting point concerns the T-cell proliferative rate in response to phages. In a study done 
by Kim et al. (2008) [70], explanted murine T-cells exposed to salmonella phages showed a higher 
proliferative response when the donor mice were pre-exposed in vivo to salmonella phages in 
comparison to T-cells isolated from non-pre-treated mice, suggesting that phages might activate per 
se the host immune system. Phage proteins differ in their capacity to activate humoral responses. 
Indeed, Dabrowska et al. (2014) [71] showed that a pre-immunization of mice with purified T4 phage 
capsid proteins gp23, gp24, Hoc, or Soc impaired the antimicrobial activity of T4 when mice were 
infected with Escherichia coli and administered with the phages. These important results obtained in 
vivo in an animal model of infection demonstrated that phages may have reduced activity to 
counteract bacteria as they are subjected to specific immunization due to phage capsid proteins. 
2.3. Route of Phage Administration in Animal Models 
Phagotherapy is efficient only when a sufficient amount of phages are able to reach the bacteria 
and kill them [72]. Three main routes of phage administration have been tested in human clinical 
trials or case reports depending on the infection type and the localization: topical, intravenous, and 
oral. Each of these routes presents some complications that still must be solved before translation of 
phage therapy in human standard medical procedures. Animal models represent a useful tool to 
investigate these aspects and to optimize phage application in humans. 
Topical phage application has been largely used for the treatment of bacterial infections 
associated with ulcers, surgical wounds, or burns [73]. Recently, several cases of compassionate 
bacteriophage treatments of diabetic foot ulcers have been reported as successful [18,19]. This is of 
particular importance, as diabetic patients are commonly immunocompromised with nephropathy 
and hepatic insufficiency, and prolonged antibiotic treatments are not well tolerated. No animal 
models of diabetic ulcers are available to test phage therapy to date, but several mouse models of 
skin ulcers, burn wounds, and infections were topically treated with phages [59,60,74] safely and 
without adverse effects. These data in mice suggest that ineffective results in two small human burn 
trials [75,76] are probably linked to an incorrect combination of modality, doses, and times of 
application rather than to ineffectiveness of phage therapy. 
Besides treatment of epithelial lesions, topical phage therapy has been successfully used to treat 
infections of specific tissues or organs. For example, inhalation of phage solutions has proven to be 
effective in counteracting MDR bacterial lung infections both in humans [77] and in mouse models 
[62,78]. 
Although the size and the immune systems of animal models are different from humans, a pre-
screening of phage compound in animals might at least optimize treatment schedules and anticipate 
any adverse/toxic effects possibly elicited by topical phage administration. 
Intravenous (IV) administration consists of injecting the phage preparations directly in the 
bloodstream, an ideal route for the treatment of bacteremia or widespread infections. The study of 
Speck and Smithyman (2015) [79] presented IV phage therapy as safe and effective, but some aspects 
have been questioned. One of the most common objections is that the phage’s lytic activity could lead 
to the release of great amounts of endotoxins directly in the bloodstream, triggering a strong immune 
response and anaphylaxis. Notably, Duplessis et al. (2008) [80] reported an anaphylactic response in 
a pediatric case after IV phage administration, and the authors did not exclude a link to endotoxin 
release. 
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Moreover, phages could be rapidly cleared from the blood, losing their effectiveness. These 
concerns must be deeply investigated prior to introducing IV phage therapy in standard medical 
procedures. Therefore, several studies about the pharmacokinetics of phages administered with IV 
injection have been conducted in rodents. Dąbrowska (2016) [81] demonstrated that, after IV injection, 
phages are not simply diluted in the body volume but are probably neutralized by anti-phage 
antibodies and removed from the bloodstream by the phagocyte system. 
Oral administration of bacteriophages involves gastro-intestinal transit and might have 
implications for the entire organism. Two main issues must be considered: first, endotoxins released 
by lysed bacteria can be absorbed and enter the blood stream, leading to systemic inflammation; 
second, the endogenous microbiome, which is crucial for digestive processes and defense against 
pathogens, can be altered. 
Several safety tests have been done to verify the efficacy of oral administration and exclude 
possible adverse effects due to the presence of the phage itself [16,68,82]. These studies also reported 
that the overall composition of the microbiota remains quite stable upon phage administration. 
Although active phages were found in fecal samples after oral administration, it is not clear if phages 
can bypass the gastric environment without being killed massively by the acid solutions. Again, in 
vivo studies using Drosophila as an animal model provide important evidence that phages can be 
orally administered with food and survive through the gastro-intestinal tract [33]. Another study on 
pigs done by Jamalludeen and colleagues (2009) [58] showed that an anti-acid pre-treatment with 
sodium bicarbonate significantly increases the number of active phages in feces and reduces the 
severity of diarrheal symptoms. Alternatively, alginate/CaCO3 microencapsulation decreases phage 
degradation in the gastric environment, thus ameliorating phage efficacy as reported by Colom and 
colleagues using a chicken model of S. enterica infection [45]. 
2.4. Methods to Improve Phage Therapy Using Animal Models 
One of the most promising aspects of phage therapy is the possibility to perform combined 
treatments with antibiotics commonly used to treat bacterial infection. This is of particular interest, 
as it reduces the time and the doses of antibiotic administration, diminishing the development of 
antibiotic-resistant bacteria and adverse effects of the drugs on the host (i.e., microbiome destruction). 
A successful combined treatment of phages and antibiotics was described by Cafora et al. (2019) [42] 
in the zebrafish CF model with P. aeruginosa infection. The reduction in mortality rate following 
phage cocktail administration was greater when phages were combined with ciprofloxacin. 
Moreover, when bacteria mutate and become phage resistant, it is possible to isolate new phages 
using the phage-resistant mutants. Although it is time consuming, this method could be used to 
overcome resistance in bacteria. Another important consideration is that the bacteria that become 
phage-resistant display increased sensitivity to the antibiotic treatment that previously failed [83]. 
For instance, Schooley et al. (2017) [10] showed that a minocycline isolate of Acinetobacter baumannii 
from a patient with severe pancreatitis displayed reduced minocycline resistance after phage therapy. 
Phages may also be considered for prophylaxis to prevent or reduce infections of different 
bacterial species, as demonstrated in several animal models [36,37,43,54,56,58]. 
A further interesting possibility to improve phage therapy is the use of liposomes and 
transfersomes for phage delivery [84]. These vesicles act by creating a broader distribution, 
preventing rapid degradation and enhancing cellular uptake [85,86]. This possibility was explored in 
a study done by Chhibber and colleagues (2017) [87] in a rat model of acute skin and soft tissue 
infection of S. aureus in which transfersomes-entrapped phages performed a faster rescue than free 
phages. A similar effect of improved phage efficacy was achieved in Colom et al. [46] by using 
liposome-entrapped phages in a chicken model of S. enterica infection. Therefore, liposomes and 
transfersomes could be a useful tool to potentiate the efficacy of phage activity. 
Last but not least, many studies successfully demonstrated the antibacterial action of some 
phage enzymes, such as endolysins, virion-associated lysins, and capsular depolymerases [88]. 
Several studies about phage-derived lysins have been concluded both in animal models and in 
humans [89], and a recent clinical trial demonstrated the safety of endolysin intravenous 
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administration [90]. In contrast to lysins, depolymerases do not lyse bacterial cells, thereby 
preventing endotoxin release and inflammation. Moreover, after capsule removal by depolymerases, 
bacteria are directly exposed to the host immune system and can be more easily killed and removed. 
The efficacy of depolymerase treatment was demonstrated in vivo in a mouse model of E. coli 
infection [91]. The same treatment successfully resulted in the rescue of both immunocompetent and 
leukopenic mice, with a higher efficiency when the enzyme was administrated shortly after infection 
[92]. One major limitation in the use of depolymerases is that, while phages can replicate 
autonomously in bacterial cells, enzymes cannot, and therefore the administration of a single dose 
could not resolve the infections. 
3. Conclusions 
In conclusion, phages proved time and again to have the appropriate characteristics to be 
introduced in human clinical treatments. Although several concerns are still present in Western 
countries, a progressive improvement of their use in clinical trials or for compassionate studies has 
been achieved. Before translating phage therapy to human clinics, some points still need to be 
clarified and excluded, as described in this review. 
Animal models are an important tool to further understand the mechanisms and the efficacies 
of bacteriophage action in vivo. Both invertebrates and vertebrates demonstrate the success of such 
treatments in a way that is cheaper, faster, and more ethical than human clinical trials. The generation 
of vertebrate animal models to test phages may give a more comprehensive understanding of the 
mechanisms triggering host immune and inflammatory response to phages, one of the most 
important concerns of phage therapy application to humans. Several strategies to improve and 
potentiate phage activity have been tested, underlining the promising strength of bacteriophages or 
their enzymes in human therapies. Among these, we cited the possibility to improve antibacterial 
action by enhancing phage delivery, the use of phages mixed in cocktails, the combination of phages 
with antibiotics, and the possibility to use phages for prophylactic treatments. All these studies can 
be easily (and cheaply) achieved in animal models before translation to humans. 
Moreover, considering that one of the most important goals of modern phage therapy is to 
rapidly identify phages able to counteract bacterial infection in compassionate studies, animals can 
be used to indicate the safety of select phages before patient treatment. Since the custom-made use of 
phages cannot be regulated right now, phage pre-screening in animals for personalized therapies 
could at least limit some of the concerns [22]. 
For all these reasons, animal models are a key tool in investigating potential phage therapies and 
introducing them to human medicine. 
Author Contributions: Conceptualization, A.B. and A.P.; writing—original draft preparation, A.B., M.C., M.A. 
and A.P.; writing—review and editing, supervision, A.P.; project administration, A.P. and M.A.; funding 
acquisition, A.P. All authors have read and agreed to the published version of the manuscript. 
Funding: This research was funded by Fondazione Ricerca Fibrosi Cistica, FFC#23/2019, “Un respiro in più 
Onlus, La mano tesa Onlus”. 
Acknowledgments: The authors thank Daniela Ghisotti and Akash Singh for their precious help in extensive 
revision of the manuscript. 
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the 
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 
publish the results. 
Abbreviations 
MDR Multi drug resistant 
CF Cystic fibrosis 
EU Endotoxin units 
FDA Food and drug administration 
CPT Center for Phage Technology 
Int. J. Mol. Sci. 2020, 21, 3715 13 of 17 
 
IV Intravenous 
PFU Plaque forming units 
References 
1. Bordet, J.; Ciuca, M. Remarques sur l’historique de recherches concernant la lyse microbienne 
transmissible. Compt. Rend. Soc. Biol. 1921, 84, 745–747. 
2. Abedon, S.T. Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. Adv. 
Drug Deliv. Rev. 2019, 145, 18–39, doi:10.1016/j.addr.2018.06.018. 
3. Hobbs, Z.; Abedon, S.T. Diversity of phage infection types and associated terminology: The problem with ‘Lytic 
or lysogenic.’ FEMS Microbiol. Lett. 2016, 363, fnw047, doi:10.1093/femsle/fnw047. 
4. Drulis-Kawa, Z.; Majkowska-Skrobek, G.; Maciejewska, B.; Delattre, A.-S.; Lavigne, R. Learning from 
bacteriophages—Advantages and limitations of phage and phage-encoded protein applications. Curr. 
Protein Pept. Sci. 2012, 13, 699–722, doi:10.2174/138920312804871193. 
5. Goh, S. Phage transduction. In Methods in Molecular Biology; Springer: Cham, Switzerland, 2016; Volume 
1476, pp. 177–185, doi: 10.1007/978-1-4939-6361-4_13. 
6. Chan, B.K.; Abedon, S.T.; Loc-Carrillo, C. Phage cocktails and the future of phage therapy. Future Microbiol. 
2013, 8, 769–783, doi:10.2217/fmb.13.47. 
7. Abedon, S.T.; Kuhl, S.J.; Blasdel, B.G.; Kutter, E.M. Phage treatment of human infections. Bacteriophage 2011, 
1, 66–85, doi:10.4161/bact.1.2.15845. 
8. Fauconnier, A. Phage therapy regulation: From night to dawn. Viruses 2019, 11, 352, doi:10.3390/v11040352. 
9. Kutter, E.; De Vos, D.; Gvasalia, G.; Alavidze, Z.; Gogokhia, L.; Kuhl, S.; Abedon, S. Phage therapy in clinical 
practice: Treatment of human infections. Curr. Pharm. Biotechnol. 2010, 11, 69–86, 
doi:10.2174/138920110790725401. 
10. Schooley, R.T.; Biswas, B.; Gill, J.J.; Hernandez-Morales, A.; Lancaster, J.; Lessor, L.; Barr, J.J.; Reed, S.L.; 
Rohwer, F.; Benler, S.; et al. Development and use of personalized bacteriophage-based therapeutic 
cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents 
Chemother. 2017, 61, doi:10.1128/AAC.00954-17. 
11. Law, N.; Logan, C.; Furr, C.; Lehman, S.; Morales, S.; Rosas, F.; Gaidamaka, A.; Bilinsky, I.; Grint, P.; Schooley, 
R.; et al. Successful bacteriophage therapy for treatment of multidrug-resistant pseudomonas aeruginosa 
infection in a cystic fibrosis patient. J. Hear. Lung Transplant. 2019, 38, S38, doi:10.1016/j.healun.2019.01.078. 
12. Dedrick, R.M.; Guerrero-Bustamante, C.A.; Garlena, R.A.; Russell, D.A.; Ford, K.; Harris, K.; Gilmour, K.C.; 
Soothill, J.; Jacobs-Sera, D.; Schooley, R.T.; et al. Engineered bacteriophages for treatment of a patient with a 
disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 2019, 25, 730–733, doi:10.1038/s41591-019-0437-z. 
13. Kutateladze, M.; Adamia, R. Phage therapy experience at the Eliava Institute. Médecine Mal. Infect. 2008, 38, 
426–430, doi:10.1016/j.medmal.2008.06.023. 
14. Boulanger, P. Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost 
particles. In Methods in Molecular Biology; Springer: Cham, Switzerland, 2009; Volume 502, pp. 227–238. 
15. Gill, J.; Hyman, P. Phage choice, isolation, and preparation for phage therapy. Curr. Pharm. Biotechnol. 2010, 
11, 2–14, doi:10.2174/138920110790725311. 
16. McCallin, S.; Alam Sarker, S.; Barretto, C.; Sultana, S.; Berger, B.; Huq, S.; Krause, L.; Bibiloni, R.; Schmitt, B.; 
Reuteler, G.; et al. Safety analysis of a Russian phage cocktail: From MetaGenomic analysis to oral application 
in healthy human subjects. Virology 2013, 443, 187–196, doi:10.1016/j.virol.2013.05.022. 
17. Gindin, M.; Febvre, H.P.; Rao, S.; Wallace, T.C.; Weir, T.L. Bacteriophage for gastrointestinal health 
(PHAGE) study: Evaluating the safety and tolerability of supplemental bacteriophage consumption. J. Am. 
Coll. Nutr. 2019, 38, 68–75, doi:10.1080/07315724.2018.1483783. 
18. Fish, R.; Kutter, E.; Bryan, D.; Wheat, G.; Kuhl, S. Resolving digital staphylococcal osteomyelitis using 
bacteriophage—A case report. Antibiotics 2018, 7, 87, doi:10.3390/antibiotics7040087. 
19. Fish, R.; Kutter, E.; Wheat, G.; Blasdel, B.; Kutateladze, M.; Kuhl, S. Compassionate use of bacteriophage 
therapy for foot ulcer treatment as an effective step for moving toward clinical trials. In Methods in Molecular 
Biology; Springer: Cham, Switzerland, 2018; Volume 1693, pp. 159–170, doi:10.1007/978-1-4939-7395-8_14. 
20. Corbellino, M.; Kieffer, N.; Kutateladze, M.; Balarjishvili, N.; Leshkasheli, L.; Askilashvili, L.; Tsertsvadze, G.; 
Rimoldi, S.G.; Nizharadze, D.; Hoyle, N.; et al. Eradication of a multidrug-resistant, carbapenemase-
producing Klebsiella pneumoniae isolate following oral and intra-rectal therapy with a custom made, lytic 
bacteriophage preparation. Clin. Infect. Dis. 2020, 70, 1998–2001, doi:10.1093/cid/ciz782. 
Int. J. Mol. Sci. 2020, 21, 3715 14 of 17 
 
21. Manohar, P.; Ramesh, N. Improved lyophilization conditions for long-term storage of bacteriophages. Sci. 
Rep. 2019, 9, 15242, doi:10.1038/s41598-019-51742-4. 
22. Melo, L.D.R.; Oliveira, H.; Pires, D.P.; Dabrowska, K.; Azeredo, J. Phage therapy efficacy: A review of the 
last 10 years of preclinical studies. Crit. Rev. Microbiol. 2020, 46, 78–99, doi:10.1080/1040841X.2020.1729695.  
23. Cohen, L.B.; Troemel, E.R. Microbial pathogenesis and host defense in the nematode C. elegans. Curr. Opin. 
Microbiol. 2015, 23, 94–101, doi:10.1016/j.mib.2014.11.009. 
24. Pukkila-Worley, R.; Ausubel, F.M. Immune defense mechanisms in the Caenorhabditis elegans intestinal 
epithelium. Curr. Opin. Immunol. 2012, 24, 3–9, doi:10.1016/j.coi.2011.10.004. 
25. Ewbank, J.J.; Zugasti, O.C. elegans: Model host and tool for antimicrobial drug discovery. Dis. Model. Mech. 
2011, 4, 300–304, doi:10.1242/dmm.006684. 
26. Augustine, J.; Gopalakrishnan, M.V.; Bhat, S.G. Application of ΦSP-1 and ΦSP-3 as a therapeutic strategy 
against Salmonella Enteritidis infection using Caenorhabditis elegans as model organism. FEMS Microbiol. Lett. 
2014, 356, 113–117, doi:10.1111/1574-6968.12493. 
27. Głowacka-Rutkowska, A.; Gozdek, A.; Empel, J.; Gawor, J.; Żuchniewicz, K.; Kozińska, A.; Dębski, J.; 
Gromadka, R.; Łobocka, M. The ability of lytic staphylococcal podovirus vB_SauP_phiAGO1.3 to coexist 
in equilibrium with its host facilitates the selection of host mutants of attenuated virulence but does not 
preclude the phage antistaphylococcal activity in a nematode infection model. Front. Microbiol. 2019, 9, 
doi:10.3389/fmicb.2018.03227. 
28. Buchon, N.; Silverman, N.; Cherry, S. Immunity in Drosophila melanogaster—From microbial recognition to 
whole-organism physiology. Nat. Rev. Immunol. 2014, 14, 796–810, doi:10.1038/nri3763. 
29. Lemaitre, B.; Hoffmann, J. The host defense of Drosophila melanogaster. Annu. Rev. Immunol. 2007, 25, 697–743, 
doi:10.1146/annurev.immunol.25.022106.141615. 
30. Hill, L.; Veli, N.; Coote, P.J. Evaluation of Galleria mellonella larvae for measuring the efficacy and 
pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection. Int. J. Antimicrob. Agents 
2014, 43, 254–261, doi:10.1016/j.ijantimicag.2013.11.001. 
31. Ramarao, N.; Nielsen-Leroux, C.; Lereclus, D. The insect Galleria mellonella as a powerful infection model 
to investigate bacterial pathogenesis. J. Vis. Exp. 2012, doi:10.3791/4392. 
32. Lindberg, H.M.; McKean, K.A.; Wang, I.-N. Phage fitness may help predict phage therapy efficacy. 
Bacteriophage 2014, 4, e964081, doi:10.4161/21597073.2014.964081. 
33. Heo, Y.-J.; Lee, Y.-R.; Jung, H.-H.; Lee, J.; Ko, G.; Cho, Y.-H. Antibacterial efficacy of phages against 
Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 2009, 
53, 2469–2474, doi:10.1128/AAC.01646-08. 
34. Jang, H.-J.; Bae, H.-W.; Cho, Y.-H. Exploitation of Drosophila infection models to evaluate antibacterial efficacy 
of phages. In Methods in Molecular Biology; Springer: Cham, Switzerland, 2019; Voluem 1898, pp. 183–190. 
35. Seed, K.D.; Dennis, J.J. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae 
infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 
2009, 53, 2205–2208, doi:10.1128/AAC.01166-08. 
36. Nale, J.Y.; Chutia, M.; Carr, P.; Hickenbotham, P.T.; Clokie, M.R.J. ‘Get in early’; biofilm and wax moth 
(Galleria mellonella) models reveal new insights into the therapeutic potential of Clostridium difficile 
bacteriophages. Front. Microbiol. 2016, 7, doi:10.3389/fmicb.2016.01383. 
37. Forti, F.; Roach, D.R.; Cafora, M.; Pasini, M.E.; Horner, D.S.; Fiscarelli, E.V.; Rossitto, M.; Cariani, L.; Briani, F.; 
Debarbieux, L.; et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa 
biofilms and treats acute infections in two animal models. Antimicrob. Agents Chemother. 2018, 62, 
doi:10.1128/AAC.02573-17. 
38. Lin, B.; Chen, S.; Cao, Z.; Lin, Y.; Mo, D.; Zhang, H.; Gu, J.; Dong, M.; Liu, Z.; Xu, A. Acute phase response 
in zebrafish upon Aeromonas salmonicida and Staphylococcus aureus infection: Striking similarities and 
obvious differences with mammals. Mol. Immunol. 2007, 44, 295–301, doi:10.1016/j.molimm.2006.03.001. 
39. Neely, M.N.; Pfeifer, J.D.; Caparon, M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. 
Immun. 2002, 70, 3904–3914, doi:10.1128/IAI.70.7.3904-3914.2002. 
40. Llamas, M.A.; van der Sar, A.M. Assessing Pseudomonas virulence with nonmammalian host: Zebrafish. In 
Methods in Molecular Biology; Springer: Cham, Switzerland, 2014; pp. 709–721, doi:10.1007/978-1-4939-0473-
0_55 
41. Al-Zubidi, M.; Widziolek, M.; Court, E.K.; Gains, A.F.; Smith, R.E.; Ansbro, K.; Alrafaie, A.; Evans, C.; 
Murdoch, C.; Mesnage, S.; et al. Identification of novel bacteriophages with therapeutic potential that target 
Int. J. Mol. Sci. 2020, 21, 3715 15 of 17 
 
Enterococcus faecalis. Infect. Immun. 2019, 87, doi:10.1128/IAI.00512-19. 
42. Cafora, M.; Deflorian, G.; Forti, F.; Ferrari, L.; Binelli, G.; Briani, F.; Ghisotti, D.; Pistocchi, A. Phage therapy 
against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model. Sci. Rep. 2019, 9, 1527, 
doi:10.1038/s41598-018-37636-x. 
43. Ahmadi, M.; Amir Karimi Torshizi, M.; Rahimi, S.; Dennehy, J.J. Prophylactic bacteriophage administration 
more effective than post-infection administration in reducing Salmonella enterica serovar enteritidis 
shedding in Quail. Front. Microbiol. 2016, 7, doi:10.3389/fmicb.2016.01253. 
44. Wernicki, A.; Nowaczek, A.; Urban-Chmiel, R. Bacteriophage therapy to combat bacterial infections in 
poultry. Virol. J. 2017, 14, 179, doi:10.1186/s12985-017-0849-7. 
45. Colom, J.; Cano-Sarabia, M.; Otero, J.; Aríñez-Soriano, J.; Cortés, P.; Maspoch, D.; Llagostera, M. 
Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy. Sci. Rep. 2017, 7, 41441, 
doi:10.1038/srep41441. 
46. Colom, J.; Cano-Sarabia, M.; Otero, J.; Cortés, P.; Maspoch, D.; Llagostera, M. Liposome-encapsulated 
bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl. Environ. Microbiol. 2015, 81, 
4841–4849, doi:10.1128/AEM.00812-15. 
47. Waseh, S.; Hanifi-Moghaddam, P.; Coleman, R.; Masotti, M.; Ryan, S.; Foss, M.; MacKenzie, R.; Henry, M.; 
Szymanski, C.M.; Tanha, J. Orally administered P22 phage tailspike protein reduces Salmonella colonization 
in chickens: Prospects of a novel therapy against bacterial infections. PLoS ONE 2010, 5, e13904, 
doi:10.1371/journal.pone.0013904. 
48. Trotereau, A.; Schouler, C. Use of a chicken embryo lethality assay to assess the efficacy of phage therapy. 
In Methods in Molecular Biology; Springer: Cham, Switzerland, 2019; Volume 1898, pp. 199–205, 
doi:10.1007/978-1-4939-0473-0_55 
49. Wills, Q.F.; Kerrigan, C.; Soothill, J.S. Experimental bacteriophage protection against Staphylococcus aureus 
abscesses in a rabbit model. Antimicrob. Agents Chemother. 2005, 49, 1220–1221, doi:10.1128/AAC.49.3.1220-
1221.2005. 
50. Kishor, C.; Mishra, R.; Saraf, S.; Kumar, M.; Srivastav, A.; Nath, G. Phage therapy of staphylococcal chronic 
osteomyelitis in experimental animal model. Indian J. Med. Res. 2016, 143, 87, doi:10.4103/0971-5916.178615. 
51. Abedon, S.T. Commentary: Phage therapy of staphylococcal chronic osteomyelitis in experimental animal 
model. Front. Microbiol. 2016, 7, doi:10.3389/fmicb.2016.01251. 
52. Yen, M.; Cairns, L.S.; Camilli, A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae 
infection in animal models. Nat. Commun. 2017, 8, 14187, doi:10.1038/ncomms14187. 
53. Nale, J.Y.; Spencer, J.; Hargreaves, K.R.; Buckley, A.M.; Trzepiński, P.; Douce, G.R.; Clokie, M.R.J. 
Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in 
vivo. Antimicrob. Agents Chemother. 2016, 60, 968–981, doi:10.1128/AAC.01774-15. 
54. Pabary, R.; Singh, C.; Morales, S.; Bush, A.; Alshafi, K.; Bilton, D.; Alton, E.W.F.W.; Smithyman, A.; Davies, J.C. 
Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. 
Antimicrob. Agents Chemother. 2016, 60, 744–751, doi:10.1128/AAC.01426-15. 
55. Alvi, I.A.; Asif, M.; Tabassum, R.; Aslam, R.; Abbas, Z.; Rehman, S.u. RLP, a bacteriophage of the family 
Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch. 
Virol. 2020, 165, 1289–1297, doi:10.1007/s00705-020-04601-x. 
56. Debarbieux, L.; Leduc, D.; Maura, D.; Morello, E.; Criscuolo, A.; Grossi, O.; Balloy, V.; Touqui, L. Bacteriophages 
can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 2010, 201, 1096–1104, 
doi:10.1086/651135. 
57. Leshkasheli, L.; Kutateladze, M.; Balarjishvili, N.; Bolkvadze, D.; Save, J.; Oechslin, F.; Que, Y.-A.; Resch, G. 
Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant 
Acinetobacter baumannii bacteraemia. J. Glob. Antimicrob. Resist. 2019, 19, 255–261, doi:10.1016/j.jgar.2019.05.005. 
58. Jamalludeen, N.; Johnson, R.P.; Shewen, P.E.; Gyles, C.L. Evaluation of bacteriophages for prevention and 
treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet. 
Microbiol. 2009, 136, 135–141, doi:10.1016/j.vetmic.2008.10.021. 
59. Chadha, P.; Katare, O.P.; Chhibber, S. In vivo efficacy of single phage versus phage cocktail in resolving 
burn wound infection in BALB/c mice. Microb. Pathog. 2016, 99, 68–77, doi:10.1016/j.micpath.2016.08.001. 
60. Trigo, G.; Martins, T.G.; Fraga, A.G.; Longatto-Filho, A.; Castro, A.G.; Azeredo, J.; Pedrosa, J. Phage therapy 
is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl. Trop. Dis. 
2013, 7, e2183, doi:10.1371/journal.pntd.0002183. 
Int. J. Mol. Sci. 2020, 21, 3715 16 of 17 
 
61. Capparelli, R.; Parlato, M.; Borriello, G.; Salvatore, P.; Iannelli, D. Experimental phage therapy against 
Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 2007, 51, 2765–2773, doi:10.1128/AAC.01513-06. 
62. Anand, T.; Virmani, N.; Kumar, S.; Mohanty, A.K.; Pavulraj, S.; Bera, B.C.; Vaid, R.K.; Ahlawat, U.; Tripathi, B.N. 
Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J. Glob. Antimicrob. 
Resist. 2020, 21, 34–41, doi:10.1016/j.jgar.2019.09.018. 
63. Abd El-Aziz, A.M.; Elgaml, A.; Ali, Y.M. Bacteriophage therapy increases complement-mediated lysis of 
bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant Pseudomonas 
aeruginosa. J. Infect. Dis. 2019, 219, 1439–1447, doi:10.1093/infdis/jiy678. 
64. Roach, D.R.; Leung, C.Y.; Henry, M.; Morello, E.; Singh, D.; Di Santo, J.P.; Weitz, J.S.; Debarbieux, L. 
Synergy between the host immune system and bacteriophage is essential for successful phage therapy 
against an acute respiratory pathogen. Cell Host Microbe 2017, 22, 38-47.e4, doi:10.1016/j.chom.2017.06.018. 
65. Łusiak-Szelachowska, M.; Żaczek, M.; Weber-Dąbrowska, B.; Międzybrodzki, R.; Letkiewicz, S.; Fortuna, W.; 
Rogóż, P.; Szufnarowski, K.; Jończyk-Matysiak, E.; Olchawa, E.; et al. Antiphage activity of sera during phage 
therapy in relation to its outcome. Future Microbiol. 2017, 12, 109–117, doi:10.2217/fmb-2016-0156. 
66. Żaczek, M.; Łusiak-Szelachowska, M.; Jończyk-Matysiak, E.; Weber-Dąbrowska, B.; Międzybrodzki, R.; 
Owczarek, B.; Kopciuch, A.; Fortuna, W.; Rogóż, P.; Górski, A. Antibody production in response to 
staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 2016, 7, 
doi:10.3389/fmicb.2016.01681. 
67. Łusiak-Szelachowska, M.; Żaczek, M.; Weber-Dąbrowska, B.; Międzybrodzki, R.; Kłak, M.; Fortuna, W.; 
Letkiewicz, S.; Rogóż, P.; Szufnarowski, K.; Jończyk-Matysiak, E.; et al. Phage neutralization by sera of 
patients receiving phage therapy. Viral Immunol. 2014, 27, 295–304, doi:10.1089/vim.2013.0128. 
68. Bruttin, A.; Brüssow, H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage 
therapy. Antimicrob. Agents Chemother. 2005, 49, 2874–2878, doi:10.1128/AAC.49.7.2874-2878.2005. 
69. Majewska, J.; Beta, W.; Lecion, D.; Hodyra-Stefaniak, K.; Kłopot, A.; Kaźmierczak, Z.; Miernikiewicz, P.; 
Piotrowicz, A.; Ciekot, J.; Owczarek, B.; et al. Oral application of T4 phage induces weak antibody 
production in the gut and in the blood. Viruses 2015, 7, 4783–4799, doi:10.3390/v7082845. 
70. Kim, K.-P.; Cha, J.-D.; Jang, E.-H.; Klumpp, J.; Hagens, S.; Hardt, W.-D.; Lee, K.-Y.; Loessner, M.J. 
PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune 
response. Microb. Biotechnol. 2008, 1, 247–257, doi:10.1111/j.1751-7915.2008.00028.x. 
71. Dąbrowska, K.; Miernikiewicz, P.; Piotrowicz, A.; Hodyra, K.; Owczarek, B.; Lecion, D.; Kaźmierczak, Z.; 
Letarov, A.; Górski, A. Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 
2014, 88, 12551–12557, doi:10.1128/JVI.02043-14. 
72. Dąbrowska, K.; Abedon, S.T. Pharmacologically aware phage therapy: Pharmacodynamic and 
pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol. Mol. Biol. 
Rev. 2019, 83, doi:10.1128/MMBR.00012-19. 
73. Morozova, V.V.; Vlassov, V.V.; Tikunova, N.V. Applications of bacteriophages in the treatment of localized 
infections in humans. Front. Microbiol. 2018, 9, doi:10.3389/fmicb.2018.01696. 
74. Kumari, S. Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused 
by Klebsiella pneumoniae in BALB/c mice. J. Microbiol. Biotechnol. 2010, 20, 935–941, doi:10.4014/jmb.0909.09010. 
75. Rose, T.; Verbeken, G.; Vos, D. De; Merabishvili, M.; Vaneechoutte, M.; Lavigne, R.; Jennes, S.; Zizi, M.; 
Pirnay, J.-P. Experimental phage therapy of burn wound infection: Difficult first steps. Int. J. Burns Trauma 
2014, 4, 66–73. 
76. Jault, P.; Leclerc, T.; Jennes, S.; Pirnay, J.P.; Que, Y.-A.; Resch, G.; Rousseau, A.F.; Ravat, F.; Carsin, H.; Le 
Floch, R.; et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by 
Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. 
Dis. 2019, 19, 35–45, doi:10.1016/S1473-3099(18)30482-1. 
77. Hoyle, N.; Zhvaniya, P.; Balarjishvili, N.; Bolkvadze, D.; Nadareishvili, L.; Nizharadze, D.; Wittmann, J.; 
Rohde, C.; Kutateladze, M. Phage therapy against Achromobacter xylosoxidans lung infection in a patient 
with cystic fibrosis: A case report. Res. Microbiol. 2018, 169, 540–542, doi:10.1016/j.resmic.2018.05.001. 
78. Waters, E.M.; Neill, D.R.; Kaman, B.; Sahota, J.S.; Clokie, M.R.J.; Winstanley, C.; Kadioglu, A. Phage therapy 
is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 2017, 72, 666–667, 
doi:10.1136/thoraxjnl-2016-209265. 
79. Speck, P.; Smithyman, A. Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol. 
Lett. 2016, 363, 242, doi:10.1093/femsle/fnv242. 
Int. J. Mol. Sci. 2020, 21, 3715 17 of 17 
 
80. Duplessis, C.; Biswas, B.; Hanisch, B.; Perkins, M.; Henry, M.; Quinones, J.; Wolfe, D.; Estrella, L.; Hamilton, T. 
Refractory pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy. J. Pediatric Infect. Dis. 
Soc. 2018, 7, 253–256, doi:10.1093/jpids/pix056. 
81. Dąbrowska, K. Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic 
and critical review. Med. Res. Rev. 2019, 39, med.21572, doi:10.1002/med.21572. 
82. Sarker, S.A.; McCallin, S.; Barretto, C.; Berger, B.; Pittet, A.-C.; Sultana, S.; Krause, L.; Huq, S.; Bibiloni, R.; 
Bruttin, A.; et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. 
Virology 2012, 434, 222–232, doi:10.1016/j.virol.2012.09.002. 
83. Chaudhry, W.N.; Concepción-Acevedo, J.; Park, T.; Andleeb, S.; Bull, J.J.; Levin, B.R. Synergy and order 
effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE 2017, 12, e0168615, 
doi:10.1371/journal.pone.0168615. 
84. Malik, D.J.; Sokolov, I.J.; Vinner, G.K.; Mancuso, F.; Cinquerrui, S.; Vladisavljevic, G.T.; Clokie, M.R.J.; 
Garton, N.J.; Stapley, A.G.F.; Kirpichnikova, A. Formulation, stabilisation and encapsulation of 
bacteriophage for phage therapy. Adv. Colloid Interface Sci. 2017, 249, 100–133, doi:10.1016/j.cis.2017.05.014. 
85. Abu Lila, A.S.; Ishida, T. Liposomal delivery systems: design optimization and current applications. Biol. 
Pharm. Bull. 2017, 40, 1–10, doi:10.1248/bpb.b16-00624. 
86. Singh, D.; Pradhan, M.; Nag, M.; Singh, M.R. Vesicular system: Versatile carrier for transdermal delivery 
of bioactives. Artif. Cells Nanomed. Biotechnol. 2015, 43, 282–290, doi:10.3109/21691401.2014.883401. 
87. Chhibber, S.; Shukla, A.; Kaur, S. Transfersomal phage cocktail is an effective treatment against methicillin-
resistant Staphylococcus aureus-mediated skin and soft tissue infections. Antimicrob. Agents Chemother. 2017, 
61, doi:10.1128/AAC.02146-16. 
88. Chan, B.; Abedon, S. Bacteriophages and their enzymes in biofilm control. Curr. Pharm. Des. 2014, 21, 85–99, 
doi:10.2174/1381612820666140905112311. 
89. Fischetti, V. Development of phage lysins as novel therapeutics: A historical perspective. Viruses 2018, 10, 
310, doi:10.3390/v10060310. 
90. Jun, S.Y.; Jang, I.J.; Yoon, S.; Jang, K.; Yu, K.-S.; Cho, J.Y.; Seong, M.-W.; Jung, G.M.; Yoon, S.J.; Kang, S.H. 
Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous 
administration among healthy volunteers. Antimicrob. Agents Chemother. 2017, 61, doi:10.1128/AAC.02629-16. 
91. Lin, H.; Paff, M.L.; Molineux, I.J.; Bull, J.J. Therapeutic application of phage capsule depolymerases against 
K1, K5, and K30 capsulated E. coli in mice. Front. Microbiol. 2017, 8, doi:10.3389/fmicb.2017.02257. 
92. Lin, H.; Paff, M.; Molineux, I.; Bull, J. Antibiotic therapy using phage depolymerases: Robustness across a 
range of conditions. Viruses 2018, 10, 622, doi:10.3390/v10110622. 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
